Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer

被引:73
作者
Du, Jiu-Wei [1 ]
Xu, Ke-Yi [1 ]
Fang, Li-Yi [1 ]
Qi, Xin-Lan [1 ]
机构
[1] Anhui Univ Sci & Technol, Sch Med, Huainan 232001, Anhui, Peoples R China
关键词
breast cancer; mouse model; interleukin-17; angiogenesis; TH17; CELLS; PREVALENCE; EXPRESSION; CARCINOMA;
D O I
10.3892/mmr.2012.1036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have suggested that interleukin-17 (IL-17), an inflammatory cytokine expressed predominantly by Th17 cells, is highly expressed in tumor tissue and may help tumors to evade immune surveillance. In this study, the significance of IL-17 expression in the tumors of murine models of breast cancer was explored. BALB/c mice were injected with MA782/5S28102 or 4T1 breast cancer cell lines to establish breast tumors. The expression of IL-17 in tumor tissue was detected by western blotting 1 and 4 weeks later, which revealed that it increased with tumor progression (P<0.05). Additionally, tumor cells and tumor-infiltrating lymphocytes were isolated from tumor tissues and cultured for 5 days with stimulation by phorbol-12-myristate-13-acetate (PM A), anti-CD3 antibody and anti-CD28 antibody. Culture media from stimulated tumor cells or tumor-infiltrating lymphocytes were harvested and their concentrations of IL-17 were tested by ELISA. Tumor cells secreted low levels of IL-17 into the media; however, lymphocytes from tumor tissues secreted high levels of IL-17, with 4T1 tumors secreting higher levels of IL-17 than MA782 tumors (P<0.05). To evaluate the effect of IL-17 on the proliferation of tumor cells, 4T1 cells were cultured in the presence or absence of recombinant IL-17 and cell numbers were counted on day 5 of culturing. Ectopic IL-17 did not promote the proliferation of tumor cells in vitro. To further understand the effect of IL-17 expression within tumors, 4T1 tumor-bearing mice were injected with recombinant IL-17 or saline via the tail vein. Tumor size was measured up to 21 days following the initial infusion of IL-17. IL-17 infusion resulted in an increased tumor volume and microvascular density (as measured by the immunohistochemical detection of CD34 expression in microvessels; P<0.05). Therefore, IL-17 expression within tumor tissues appears to originate from tumor-infiltrating lymphocytes and is likely to promote tumor growth by enhancing angiogenesis.
引用
收藏
页码:1099 / 1102
页数:4
相关论文
共 16 条
[1]   The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease [J].
Afzali, B. ;
Lombardi, G. ;
Lechler, R. I. ;
Lord, G. M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 148 (01) :32-46
[2]  
Fossiez F, 1998, Int Rev Immunol, V16, P541, DOI 10.3109/08830189809043008
[3]   Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J].
Harrington, LE ;
Hatton, RD ;
Mangan, PR ;
Turner, H ;
Murphy, TL ;
Murphy, KM ;
Weaver, CT .
NATURE IMMUNOLOGY, 2005, 6 (11) :1123-1132
[4]   Current management and treatment strategies for breast cancer [J].
Howard, John H. ;
Bland, Kirby I. .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2012, 24 (01) :44-48
[5]   Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment [J].
Kryczek, Ilona ;
Wei, Shuang ;
Zou, Linhua ;
Altuwaijri, Saleh ;
Szeliga, Wojciech ;
Kolls, Jay ;
Chang, Alfred ;
Zou, Weiping .
JOURNAL OF IMMUNOLOGY, 2007, 178 (11) :6730-+
[6]   High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas [J].
Le Gouvello, S. ;
Bastuji-Garin, S. ;
Aloulou, N. ;
Mansour, H. ;
Chaumette, M-T ;
Berrehar, F. ;
Seikour, A. ;
Charachon, A. ;
Karoui, M. ;
Leroy, K. ;
Farcet, J-P ;
Sobhani, I. .
GUT, 2008, 57 (06) :772-779
[7]   TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms [J].
Novitskiy, Sergey V. ;
Pickup, Michael W. ;
Gorska, Agnieszka E. ;
Owens, Philip ;
Chytil, Anna ;
Aakre, Mary ;
Wu, Huiyun ;
Shyr, Yu ;
Moses, Harold L. .
CANCER DISCOVERY, 2011, 1 (05) :430-441
[8]   IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis [J].
Numasaki, M ;
Watanabe, M ;
Suzuki, T ;
Takahashi, H ;
Nakamura, A ;
McAllister, F ;
Hishinuma, T ;
Goto, J ;
Lotze, MT ;
Kolls, JK ;
Sasaki, H .
JOURNAL OF IMMUNOLOGY, 2005, 175 (09) :6177-6189
[9]   The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases [J].
Pappu, Rajita ;
Ramirez-Carrozzi, Vladimir ;
Sambandam, Arivazhagan .
IMMUNOLOGY, 2011, 134 (01) :8-16
[10]   Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer [J].
Peng, Jing ;
Sengupta, Surojeet ;
Jordan, V. Craig .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) :481-499